Outlook on the Worldwide CAR T-Cell Therapy for Multiple Myeloma (2017 to 2030) – Featuring MolMed, Celgene & Cartesian Therapeutics Among Others…

Dublin, April 07, 2020 (GLOBE NEWSWIRE) -- The "CAR T-Cell Therapy for Multiple Myeloma - Market Insights and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the CAR T-Cell Therapy use for Multiple Myeloma as well as the CAR T-Cell Therapy market trends for Multiple Myeloma in the 6MM i.e., United States and EU5 (Germany, Spain, Italy, France and the United Kingdom).

The Multiple Myeloma CAR T-Cell Therapy market report provides current treatment practices, emerging drugs, CAR T-Cell Therapy market share of the various CAR T-Cell Therapies for Multiple Myeloma, the individual therapies, current and forecasted Multiple Myeloma CAR T-Cell Therapy market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Multiple Myeloma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

Scope of the Report

Report Highlights

Key Questions

Market Insights:

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

Reasons to Buy

Key Topics Covered:

1 Key Insights

2 Executive Summary

3 CAR T-Cell Therapy Market Overview at a Glance3.1 Market Share (%) Distribution of CAR T-Cell Therapy for MM in 2030

4 CAR T-Cell Therapy Background and Overview4.1 Introduction4.1.1 CARs Generations4.1.2 Genetic Engineering of T-Cells4.1.3 How CAR T-Cell Therapy Works4.2 The promise of CAR T-cell targeting B cell maturation antigen (BCMA) in multiple myeloma4.3 Current challenges in CAR T4.3.1 Therapeutic side effects4.3.2 CAR T-cells lack of success4.4 CAR T-cell therapy: Route to reimbursement4.5 Unmet needs

5 CAR T-Cell Therapy for Multiple Myeloma (MM): 6 Major Market Analysis5.1 Key Findings5.2 Market Size of CAR T-Cell Therapy in 6MM5.2.1 Market Size of CAR T-Cell Therapy by Therapies

6 Market Outlook

7 Emerging Drug Profiles for Multiple Myeloma7.1 bb2121: Celgene Corporation7.1.1 Product Description7.1.2 Research and Development7.1.3 Product Development Activities7.2 JNJ-68284528 (LCAR-B38M): Janssen Research & Development7.2.1 Product Description7.2.2 Research and Development7.2.3 Product Development Activities7.3 P-BCMA-101: Poseida Therapeutics7.3.1 Product Description:7.3.2 Research and Development7.3.3 Product Development Activities7.4 CAR-CD44v6: MolMed S.p.A.7.4.1 Product Description7.4.2 Research and Development7.4.3 Product Development Activities7.5 JCARH125 (Orvacabtagene autoleucel): Celgene Corporation7.5.1 Product Description7.5.2 Research and Development7.5.3 Product Development Activities7.6 Descartes-08: Cartesian Therapeutics7.6.1 Product Description7.6.2 Research and Development7.7 CT053 : CARsgen Therapeutics)7.7.1 Product Description7.7.2 Research and Development7.7.3 Product Development Activities

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/cfvheq

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Link:
Outlook on the Worldwide CAR T-Cell Therapy for Multiple Myeloma (2017 to 2030) - Featuring MolMed, Celgene & Cartesian Therapeutics Among Others...